Moderna, Inc. (MRNA)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 02:38PM EDT. Market open.
| Previous close | 132.90 |
| Open | 133.00 |
| Bid | 139.70 x 100 |
| Ask | 142.77 x 200 |
| Day's range | 131.72 - 142.76 |
| 52-week range | 62.55 - 142.79 |
| Volume | |
| Avg. volume | 3,829,277 |
| Market cap | 53.707B |
| Beta (5Y monthly) | 1.57 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -15.60 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 137.59 |
ZacksThe Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers are included in this Analyst Blog.
ZacksBiotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
Novavax, Inc (NVAX) and Fulcrum Therapeutics, Inc (FULC) are in the spotlight following license agreements with pharma giant Sanofi.
Investor's Business DailyModerna Stock Rebounds From Its RSV Vaccine Fallout — Is It A Buy, Again?
Moderna is on the rise after the Food and Drug Administration delayed a decision on its RSV vaccine. But is MRNA stock, once again, a buy?
© 2024 Yahoo. All rights reserved.